![](/images/Company_Logo/company_logo_default.png)
TargaGenix Inc Profile last edited on: 1/29/2024
CAGE: 76GC1
UEI: GZKVUPMHUBF3
Business Identifier: Novel cancer therapies targeting cancer stem cells Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 01
County: Suffolk
Congr. District: 01
County: Suffolk
Public Profile
Targeting cancer stem cells and bulk tumor cells, TargaGenix, Inc. is developing a novel therapy for treatment of cancer: novel compounds that are effective on both drug-resistant tumors and cancer stem cells. The firm's product - DHA-SBT-1214 - came out of a 10+ year effort to discover new molecules that were effective against chemotherapy resistant tumors and has been shown in preclinical models that it can treat and cure animals with tumor types that are resistant to current chemotherapy treatments. Work undertaken by the firm has shown that SBT-1214 is able to effectively down-regulate stemness gene expression and kill cancer stem cells. Additional chemical modifications and a novel fatty-acid based nanoemulsion formulation result in a drug that has improved pharmacokinetics and pharmacodynamics properties as well as reduced toxicity.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
5-9Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2016 | 2 | NIH | $2,284,577 | |
Project Title: R&D Nanoemulsion Formulation and Ind Enabling Studies of a Novel Center Stem Cell Cytotoxic Agent |
Key People / Management
James Egan -- President and CEO
Company News
There are no news available.